Oral Bioavailability Enhancement of Amisulpride: Complexation and its Pharmacokinetics and Pharmacodynamics Evaluations

Author(s): Prajapati Jagruti B.*, Sawant Krutika K., Bhramanand Dubey.

Journal Name: Drug Metabolism Letters

Volume 13 , Issue 2 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Many CNS drugs have low bioavailability due to their poor water solubility of extensive first-pass metabolism and hence have less effectiveness.

Objective: The present study aims to enhance the solubility and oral bioavailability of poorly watersoluble antipsychotic drug Amisulpride (AMS) through complexation with 2-hydroxypropyl β- cyclodextrin (HPβCD). It has slow and erratic absorption after oral administration.

Methods: This report describes the study of the phase solubility diagram, preparation of the inclusion complex and tablet of prepared inclusion complex, characterization of the physico-chemical properties of the inclusion complex and tablet.

Results: In-vitro study (100 % drug release in 15 minutes), and in-vivo study of an AL-type (linear type) phase solubility diagram indicated a complex of AMS-HP-β-CD with the constant complex formation of 13245 M−1 at 37°C. The complex formation was confirmed by DSC, IR, and X-ray diffraction. The extent of absorption of the complex was determined in rats and was compared with that of pure drug and the market product. The peak plasma concentration of pure drug was 30.05 ± 1.3 ng/ml (Cmax) at 60 ± 3 min, whereas with the market product the value was 54.85 ± 1.2 ng/ml at 40 ± 1 min and with AMS-HPβCD inclusion complex the value was 79.01 ± 1.5 ng/ml. The AUCtot of the pure drug was 2980.34±3.6, the market product was 7238.73±2.9 and of the inclusion complex was 11871.1±2.8.

Conclusion: Pharmacodynamic studies in mice showed improved effectiveness of drug compared to pure drug. The oral bioavailability of AMS was improved from 48% to 78%.

Keywords: Amisulpride (AMS), HP-β-CD, complexation, oral bioavailability, pharmacodynamics, pharmacokinetics.

[1]
Boyer, P.; Lecrubier, Y.; Puech, A.J.; Dewailly, J.; Aubin, F. Treatment of negative symptoms in schizophrenia with amisulpride. Br. J. Psychiatry, 1995, 166, 68-72.
[2]
Gerold, M. Complexation and Cyclodextrins. In: Encyclopedia of Pharmaceutical Technology by Marcel Dekkar; , 2002; pp. 531-558.
[3]
Duchene, D.; Wouessidjew, D. Pharmaceutical uses of Cyclodextrins and derivative. Drug Dev. Ind. Pharm., 1990, 16(17), 2487-2499.
[http://dx.doi.org/10.3109/03639049009058543]
[4]
Background review for cyclodextrins used as excipients EMA/CHMP/333892/2013. [WWW Document]. URL: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2014/12/WC500177936.pdf [accessed 02 05 2015].
[5]
Suihko, E.; Korhonen, O.; Järvinen, T.; Ketolainen, J.; Jarho, P.; Laine, E.; Paronen, P. Complexation with tolbutamide modifies the physicochemical and tableting properties of hydroxypropyl-beta-cyclodextrin. Int. J. Pharm., 2001, 215(1-2), 137-145.
[http://dx.doi.org/10.1016/S0378-5173(00)00682-7] [PMID: 11250099]
[6]
Tirucherai, G.S.; Mitra, A.K. Effect of hydroxypropyl beta cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of ganciclovir. AAPS PharmSciTech, 2003, 4(3)E45
[http://dx.doi.org/10.1208/pt040345] [PMID: 14621977]
[7]
Higuchi, T.; Connors, K.A. Phase-Solubility techniques. Adv. Anal. Chem. Instrumental, 1965, 4, 117-212.
[8]
Loftsson, T.; Brewster, M.E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci., 1996, 85(10), 1017-1025.
[http://dx.doi.org/10.1021/js950534b] [PMID: 8897265]
[9]
Krenn, M.; Gamcsik, M.P.; Vogelsang, G.B.; Colvin, O.M.; Leong, K.W. Improvements in solubility and stability of thalidomide upon complexation with hydroxypropyl-beta-cyclodextrin. J. Pharm. Sci., 1992, 81(7), 685-689.
[http://dx.doi.org/10.1002/jps.2600810719] [PMID: 1403704]
[10]
Veiga, F.; Fernandes, C.; Maincent, P. Influence of the preparation method on the physicochemical properties of tolbutamide/cyclodextrin binary systems. Drug Dev. Ind. Pharm., 2001, 27(6), 523-532.
[http://dx.doi.org/10.1081/DDC-100105177] [PMID: 11548859]
[11]
Jambhekar, S.; Casella, R.; Maher, T. The physicochemical characteristics and bioavailability of indomethacin from s-cyclodextrin, hydroxy-ethyls-cyclodextrin and hydroxyrpopyl-s-cyclodextrin complexes. Inter. J. Pharm., 2004, 270, 149-166.
[12]
Raguia, A.S.; Iman, S.A.; Rehab, N. In vitro and in vivo evaluation of nimesu lide lyophilized orally disintegrating tablets. Eur. J. Pharm. Biopharm., 2009, 73(1), 162-171.
[http://dx.doi.org/10.1016/j.ejpb.2009.04.005]
[13]
Modasiya, M.K. Design and characterizantion of fast dissolving tablets of Piroxicam. Int. J. Pharm. Tech. Res., 2009, 1(2), 353-357.
[14]
Colonna, L.; Saleem, P.; Dondey-Nouvel, L.; Rein, W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int. Clin. Psychopharmacol., 2000, 15(1), 13-22.
[http://dx.doi.org/10.1097/00004850-200015010-00002] [PMID: 10836281]
[15]
Richard, D.; Marry, J. lippincott’s Willium Wilkins In: Lippincott’s illustrated reviews; , 2006.
[16]
Coukell, J.; Spencer, A.; Caroline, M. Amisulpride: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. Drugs, 2001, 61(14), 2123-2150.
[17]
Mariusz, P.; Joanna, W. Antidepressant-like activity of amisulpride in two animal models of depression. J. Psychopharmacol., 2000, 6, 46-52.
[18]
Frederique, L.; Denis, W.; Christine, H.; Dominique, D. Preparation and stability of iodine/a-cyclodextrin inclusion complex. Drug Dev. Ind. Pharm., 1992, 18(7), 1853-1863.
[19]
Sunil, J.; Casella, R.; Maher, T. The physicochemical characteristics and bioavailability of indomethacin from ß-cyclodextrin, hydroxy-ethyl ß-cyclodextrin and hydroxyrpopyl-ß-cyclodextrin complexes. Inter. J. Pharm., 2004, 270, 149-166.
[20]
Kang, J.; Kumar, V.; Yang, D.; Chowdhury, P.R.; Hohl, R.J. Cyclodextrin complexation: Influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent. Eur. J. Pharm. Sci., 2002, 15(2), 163-170.
[http://dx.doi.org/10.1016/S0928-0987(01)00214-7] [PMID: 11849913]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 2
Year: 2019
Page: [132 - 144]
Pages: 13
DOI: 10.2174/1872312813666191018152226

Article Metrics

PDF: 15
HTML: 6